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Abstract: The glycolytic-based metabolism of cancers promotes an acidic microenvironment that is responsible for 
increased aggressiveness. However, the effects of acidosis on tumour metabolism have been almost unexplored. By 
using capillary electrophoresis with time-of-flight mass spectrometry, we observed a significant metabolic difference 
associated with glycolysis repression (dihydroxyacetone phosphate), increase of amino acid catabolism (phospho-
creatine and glutamate) and urea cycle enhancement (arginino succinic acid) in osteosarcoma (OS) cells compared 
with normal fibroblasts. Noteworthy, metabolites associated with chromatin modification, like UDP-glucose and N8-
acetylspermidine, decreased more in OS cells than in fibroblasts. COBRA assay and acetyl-H3 immunoblotting indi-
cated an epigenetic stability in OS cells than in normal cells, and OS cells were more sensitive to an HDAC inhibitor 
under acidosis than under neutral pH. Since our data suggest that acidosis promotes a metabolic reprogramming 
that can contribute to the epigenetic maintenance under acidosis only in tumour cells, the acidic microenvironment 
should be considered for future therapies.
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Introduction
The self-organizing adaptive system to microen-
vironmental stress is a common hallmark of all 
cancer types. Among metabolic alterations, 
increased glycolysis is one of the most studied. 
Although an imbalance between enhanced oxy-
gen consumption by cancer cells and insuffi-
cient oxygen delivery from the aberrant tumour 
vasculature might be the main reason for such 
phenomenon, glycolysis increases even in the 
presence of oxygen, as clearly described by 
Otto Warburg in 1930 [1, 2]. The high-rate ener-
getic glycolytic metabolism of cancer cells 
causes high lactic acid production and a high 
proton efflux. Notably, low pH is one of the main 
pathophysiological traits of solid tumours at a 
very early stage. However, thanks to tumour 
plasticity, malignant cells quickly learn how to 
survive and to progress under an acidic extra-
cellular environment [3]. We recently confirmed 
the highly acidifying activity of sarcoma cells 
and their ability to survive under acidic pH; and, 
like in other cancers, a low extracellular pH in 
these tumours induces an increased invasive 
behaviour [4, 5]. Nowadays, it is clear that 
extracellular acidity is a consequence of the 
altered metabolism of cancer cells. Several 
studies reported that hypoxia promotes an 
increase in glycolysis through the activation of 
the hypoxia inducible factor-1 (HIF-1), and might 
be one of the main causes of tumour acidosis 
[6-8]. An increased glycolytic rate is part of 
the so-called “tumour fermentation”, which in- 
cludes also glutaminolysis, amino acid catabo-
lism, and uncoupled tricarboxylic acid (TCA) 
cycle [9, 10]. However, the effects of acidosis 
on tumour metabolism are almost unknown. 
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One study in breast cancer under short-term 
acidosis reported an imbalance of tumour fer-
mentation versus a glutaminolytic metabolism, 
involving pentose phosphate and fatty acid 
metabolism, associated with a strong reduc-
tion in glycolysis and increased TCA cycling 
[11]. The shift to glutamine metabolism was 
also recently demonstrated under chronic aci-
dosis in models of cervix cancer, squamous 
carcinoma and colon cancer cell lines that were 
cultured at a low pH for several weeks [12]. 
However, metabolic changes of cancer cells 
when maintained under acidosis have not been 
completely elucidated, and, most importantly, 
the metabolic adaptation of cancer cells to aci-
dosis has never been compared with the meta-
bolic response of normal cells. New experimen-
tal approaches may improve our knowledge in 
this field and may support the identification of 
novel and more specific anticancer therapies. 
In this study, to pinpoint for the first time the 
different metabolic profiles between osteosar-
coma (OS) cells and normal human fibroblasts 
(Fb) under short-term acidosis, we used capil-
lary electrophoresis with time-of-flight mass 
spectrometry (CE-TOFMS) [13]. We decided to 
evaluate the metabolic adaptation of cancer 
to the neutral condition, in the single group of 
cells, cancer or normal cell group. Finally, to 
make sure not to lose additional metabolic 
pathways associated with the metabolic repro-
gramming of tumour cells when cultured under 
acidosis, we also performed the analysis of the 
differences of the concentration of intracellular 
metabolites between the acidic condition in 
respect to the neutral condition only in OS cells.
The intracellular availability of specific metabo-
lites dictates the efficacy and specificity of 
enzymatic reactions including for epigenetic 
regulation [14]. Thus, altered cancer metabo-
lism associated with extracellular acidosis may 
potentially modulate the epigenetic state of 
cancer cells as a response to cellular stress. 
Indeed, intracellular pH that is affected by 
extracellular pH [15] may modulate histone 
acetylation and vice versa [16]. Epigenetic al- 
terations of chromatin can affect gene expres-
sion profiles and contribute to tumourigenesis 
and tumour progression [17]. Therefore, in this 
study we also screened alterations of the epi-
genetic profiles-DNA methylation and histone 
acetylation-of OS cells and compared it with 
those of normal Fb. 
Figure 1. Graphical summary of the experimental protocol: The different cell 
models (HOS, MG-63, Saos-2, TIG-121, TIG-108) were cultured for 24 hours 
in the Acidic or Neutral culture medium. Samples were obtained both from 
the cell lysates (Cells), and by using the culture supernatant (Medium). DNA, 
RNA, proteins and metabolites were extracted, and analysed by COBRA, RNA-
seq, Western blots, and CE-TOFMS assays. The supernatant medium was 
also analyzed by CE-TOFMS assay for metabolomics screening to evaluate, 
together with the analysis on cell lysates, the accumulation, consumption, 
productive increase, or decrease rates relative to each metabolite.
cells in respect to the normal 
cells in the short term, rather 
than to study the consequenc-
es of the chronic exposure to 
acidosis for clonal evolution. 
Indeed, we intended to evalu-
ate the prompt reaction of 
tumour cells to a hostile mic- 
roenvironment. The proposed 
model allows the identifica-
tion of the first key passages 
that tumour cells pass throu- 
gh, to survive and compete 
with normal cells in the tu- 
mour microenvironment. Fir- 
st, we identified those metab-
olites that significantly differ 
between OS and Fb cells 
under acidosis. Then, we con-
firmed that the identified 
metabolites were specifically 
associated with the tumour 
cells rather than with normal 
cells, by analyzing the varia-
tion of the concentrations of 
the identified metabolites un- 
der acidic condition in respect 
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Materials and methods 
Cell lines 
Human OS cells (MG-63, HOS) and normal 
fibroblasts (TIG-108, TIG-121) were obtained 
from the Japanese Collection of Research Bio- 
resources (Osaka, Japan). Mesenchymal stro-
mal cell (MSC) primary cultures (#305526, 
#351482; #326162) were acquired from Lonza 
(MD). Saos-2 human OS cells were obtained 
from RIKEN BioResource Center (RIKEN BRC, 
Tsukuba, Japan). Cells were cultured in Dul- 
becco’s modified Eagle’s medium containing 
10% fetal bovine serum, supplemented with 
penicillin (50 units/mL) and streptomycin (50 
mg/mL) with 10 mM 4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid to adjust the pH at 
7.4. Cells were incubated at 37°C in a humidi-
fied chamber supplemented with 5% CO2. For 
the different assays, cells were seeded and 
treated with different methods according to the 
specific assay, as explained as follows, and as 
summarized in Figure 1.
Metabolites extraction 
Extracellular acidosis was obtained by adding 
to the media 10 mM piperazine-1,4-bis(2-eth-
anesulfonic acid) to adjust the pH at 6.5. Cells 
were maintained at a low pH for 24 h. To evalu-
ate the content of intracellular metabolites, 
cells were cultured in 100 mm diameter dishes 
and washed twice with 5% mannitol solution 
(10 mL first and then 2 mL). Then, the cells 
were treated with 800 μL ice-cold methanol 
and left for 30 s in order to inactivate enzymes. 
Next, the cell extract was treated with 550 µL 
of Milli-Q water containing 10 μM internal stan-
dards (#H3304-1002, Human Metabolome 
Technologies, Inc.) and left for another 30 s. 
Extracellular culture medium (200 µL) was 
added to 500 μL ice-cold methanol containing 
internal standards. Once the extracts were 
obtained, they were centrifuged at 2,300 × g at 
4°C for 5 min. The upper aqueous layer (1 mL) 
was centrifugally filtered through a Millipore 
5-kDa cut-off filter at 9,100 × g at 4°C for 180 
min to remove proteins. The filtrate was cen-
trifugally concentrated and re-suspended in 50 
µL of Milli-Q water for CE-TOFMS analysis.
CE-TOFMS analysis of intracellular metabolites 
and data processing 
Metabolome measurements and data process-
ing were carried out through a facility service at 
Human Metabolome Technology Inc. (HMT). 
Briefly, CE-TOFMS was carried out using an 
Agilent CE Capillary Electrophoresis System 
equipped with an Agilent 6210 Time of Flight 
mass spectrometer, Agilent 1100 isocratic 
HPLC pump, Agilent G1603A CE-MS adapter 
kit, and Agilent G1607A CE-ESI-MS sprayer kit 
(Agilent Technologies). The systems were con-
trolled by Agilent G2201AA ChemStation soft-
ware version B.03.01 for CE (Agilent Tech- 
nologies). The metabolites were analysed by 
using a fused silica capillary (50 µm internal 
diameter × 80 cm total length), with commer-
cial electrophoresis buffer (#H3301-1001 for 
cation analysis and #H3302-1021 for anion 
analysis, HMT) as the electrolyte. The sample 
was injected at a pressure of 50 mbar for 10 s 
(approximately 10 nL) in cation analysis and 25 
s (approximately 25 nL) in anion analysis. The 
spectrometer was scanned from 50 to 1,000 
m/z. Other conditions were as in the described 
previously [18-20]. Peaks were extracted using 
automatic integration software MasterHands 
(Keio University) in order to obtain peak infor-
mation including m/z, migration time for 
CE-TOFMS measurement (MT) and peak area 
[21]. Signal peaks corresponding to isoto-
pomers, adduct ions, and other product ions of 
known metabolites were excluded; remaining 
peaks were annotated with putative metabo-
lites from the HMT metabolite database based 
on their MTs and m/z values determined by 
TOFMS. The tolerance range for the peak anno-
tation was configured at ± 0.5 min for MT and ± 
10 ppm for m/z. In addition, peak areas were 
normalized against those of the internal stan-
dards, and the resultant relative area values 
were further normalized according to the sam-
ple amount.
Hierarchical cluster analysis (HCA) and princi-
pal component analysis (PCA) were performed 
by HMT proprietary software PeakStat and 
SampleStat, respectively. Detected metabo-
lites were plotted on metabolic pathway maps 
using the VANTED (Visualization and Analysis of 
Networks containing Experimental Data) soft-
ware [22].
RNA extraction and RNA-seq analysis 
Total RNA from each cell was extracted, 
prepared as the library for RNA-seq, and applied 
to Illumina Genome Analyzer GAIIx sequencing. 
Sequencing reads were aligned, mapped to 
Human genome build 19 (hg19) as a reference, 
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and quantified as the expression data of 
transcriptome. The more detailed method was 
described in Supplementary information.
DNA isolation and treatment with sodium 
bisulfite 
Cells were washed with phosphate-buffered 
saline (PBS) and suspended in lysis buffer (10 
mM Tris-HCl and 50 mM EDTA, both at pH 8.0, 
10 mM NaCl, 2% N-lauryl sarcosyl, and 200 µg/
mL proteinase K). The mixture was incubated 
for 20 h at 55°C, followed by phenol chloroform 
extraction and ethanol precipitation. DNA from 
cell lines was extracted using QIAamp DNA 
Blood Mini Kits (QIAGEN). Bisulfite treatment 
was performed according to the method of 
Clark et al. [23] with variations detailed by 
Frevel et al. [24]. The bisulfite reaction, under 
mineral oil, was performed at 55°C for 16 h in 
a total volume of 525 μL containing 2.4 M sodi-
um bisulfite and 123 mM hydroquinone (Sigma). 
Reactions were desalted using a QIAEX II gel 
extraction kit (QIAGEN). DNA was eluted in 50 
μL of H2O, incubated with 5 μL of 3 M NaOH for 
15 min at 37°C neutralized with ammonium 
acetate (final concentration of 3 M), and etha-
nol precipitated. Bisulfite-treated DNA was then 
resuspended in 25 μL of H2O and stored at 
-20°C.
Combined bisulfite restriction analysis (CO-
BRA) for LINE1 
To screen the methylation profile of genomic 
DNA methylation, we used COBRA for LINE1 
[25, 26], and the DNA extract from NEC8 tes-
ticular embryonal carcinoma cell used as a 
highly unmethylated control. Methylation of the 
LINE1 promoter was investigated as follows: 
PCR amplification was performed in a 25 μL 
volume using Ex Taq buffer (Takara) under the 
following conditions: 2 mM MgCl2, 200 mM 
each deoxynucleotide triphosphate, 0.8 mM 
final concentration of each primer and 0.6 un- 
it of Ex Taq (Takara). The primer sequences 
related to the LINE1 promoter region we- 
re: 5’-TTGAGTTGTGGTGGGTTTTATTTAG-3’ (496-
520, X58075) and 5’-TCATCTCACTAAAAAATA- 
CCAAACA-3’ (108-132, X58075). PCR cycling 
conditions were 95°C for 30 s, 50°C for 30 s, 
and 72°C for 30 s for 35 cycles. The final PCR 
product was digested with the HinfI restriction 
enzyme. The digested PCR products were sepa-
rated by electrophoresis on 6% polyacrylamide 
gels. In COBRA analysis, the lower digested 
multiple bands represent methylated repetitive 
elements, and the upper top undigested band 
represents unmethylated repetitive elements 
or repetitive elements with a mutated restric-
tion site. Following gel electrophoresis and 
ethidium bromide staining, the PCR bands were 
quantified through densitometric analysis to 
evaluate the degree of methylation determined 
for LINE1 elements in OS, Fb, and MSC cells. As 
unmethylated DNA control, DNA from NEC8, a 
testicular embryonal carcinoma cell line was 
used [26]. 
Western blotting 
Cells were lysed in Laemmli-sodium dodecyl 
sulphate (SDS) buffer, subjected to SDS-po- 
lyacrylamide gel electrophoresis, and electro-
transferred to membrane filters (Immuno-Blot 
PVDF membranes, Bio-Rad Laboratories). After 
blocking the filters with TBS-T (10 mM Tris-HCl 
(pH 7.6), 150 mM sodium chloride, 0.1% Tween 
20) containing 5% bovine serum albumin (BSA), 
they were incubated overnight with the primary 
antibodies in TBS-T containing 2% BSA at 4°C. 
The filters were then washed in TBS-T and incu-
bated for 1 h in horseradish peroxidase-conju-
gated anti-mouse or anti-rabbit IgG (TrueBlotTM, 
eBioscience, Affymetrix Japan) or anti-goat 
antibodies (Santa Cruz Biotechnology) diluted 
1:1,000,000 in TBS-T containing 2% BSA. After 
several washes with TBS-T, the immunoreac-
tion was detected using the ECL system (GE 
Healthcare) with LAS4000 (Fujifilm) and quanti-
fied with Multi gauge (Fujifilm), using an anti-α 
tubulin (DM 1A) or anti-TATA-binding protein 
(TBP) antibody (Sigma) as an internal control. 
For the analysis of the acetylation of histone H3 
in cells treated with MC1742, cells were seeded 
and let to adhere for 24 h in complete medium. 
Then, the medium was replaced with complete 
medium at pH 6.5 or pH 7.4, with or without 
HDACi MC1742 (1 or 2 μM). After 24 h, cell 
lysates were obtained after a washing in PBS 
with the hot lysis buffer. The cell lysates were 
prepared by direct boiling in SDS lysis buffer 
(1% SDS, 20 mM Tris HCl pH 7.6, 5% β-mer- 
captoethanol, 1 mM sodium ortho-vanadate) 
for 3 min followed by ultrasonication for 10-15 
s. Equal amounts of protein lysates were sub-
jected to SDS-PAGE. Antibodies against histone 
de-acetylase 1 (HDAC1: 10E2) and acetyl-his-
tone H3 (Ac-H3: #06-599) were purchased 
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from Cell Signalling Technology and Millipore, 
respectively. The experiments were repeated 
more than three times. 
Viability and growth assay 
Viability: Cells were seeded in 96-well plates 
with complete medium. After 24 h, the medium 
was changed with complete medium at pH 
6.5 or pH 7.4, with or without HDAC inhibitor 
(HDACi) MC1742 (0.5, 1, or 2 μM). After addi-
tional 72 h, the cell number was indirectly eval-
uated by an acid phosphatase assay, as previ-
ously described [4]. Briefly, the medium was 
removed and each well was washed once with 
PBS, and the medium was replaced with 100 
μL of buffer containing 0.1 M sodium acetate 
(pH 5.0), 0.1% Triton X-100, and 5 mM p-nitro-
phenil phosphate. The plate was placed at 
37°C incubator for 3 h. The reaction was 
stopped with the addition of 10 μL of a 1 N 
NaOH, and colour development was assayed 
at 405 nm using a microplate reader (Tecan 
Infinite F200pro, Männedorf, Switzerland). The 
experiments were repeated with four repli- 
cates.
Growth assay: Cells were seeded in 6-well 
plates in complete medium. After 24 h, the 
medium was changed with complete medium 
at pH 6.5 or pH 7.4, with or without MC1742 (1, 
2 μM). Cell growth was evaluated soon after the 
population doubling, at 24 h for pH 7.4 and at 
48 h for pH 6.5, by the direct counting of cells 
using erythrosine dye (Sigma). The experiments 
were repeated with four replicates.
Cell cycle analysis
DNA content and bromodeoxyuridine (BrdU) 
incorporation were determined, by simultane-
ous analysis of propidium iodide (PI) and of fluo-
rescein isothiocyanate (FITC)-conjugated anti-
BrdU antibody. Cells were seeded at low density 
in complete medium, and after 24 h the medi-
um was changed with complete medium at pH 
6.5 or 7.4. After additional 48 h, cells were 
incubated with 10 mM BrdU for 60 min before 
harvesting. Cells were collected by trypsiniza-
tion, followed by fixation in 40% ethanol for 20 
min. Partial DNA denaturation was performed 
by incubating cells in HCl, followed by neutral-
ization with sodium tetraborate. Samples were 
then exposed to a monoclonal anti-BrdU FITC 
antibody, washed, and finally stained with 2.5 
mg/mL PI. Then, flow cytometric analysis was 
performed. The experiment was repeated three 
times.
Table 1. Metabolites with lower intracellular concentration in osteosarcoma cells than in normal fibro-
blasts under acidosis analysed by CE-TOFMS 
Compound name Category
OS Fb
OS/Fb P-valueMean 
[pmol/109 cells]
SD Mean 
[pmol/109 cells]
SD
Dihydroxyacetone phosphate Glycolysis 4.65 2.86 15.65 0.33 0.30 0.0295*
Phosphocreatine Protein metabolism 34.40 9.01 194.80 5.01 0.18 0.0003**
Glu Glycogenic amino acid 237.14 123.82 642.46 76.19 0.37 0.0424*
Argininosuccinic acid Uremic toxin 0.98 0.26 5.30 0.53 0.19 0.0398*
ATP Purine bases 807.41 217.89 1618.76 100.12 0.50 0.0218*
GTP Purine bases 34.66 8.57 100.27 7.71 0.35 0.0169*
CTP Pyrimidine bases 67.44 17.70 118.23 6.50 0.57 0.0407*
UTP Pyrimidine bases 220.87 152.84 1057.52 142.54 0.21 0.0379*
UDP-glucose, UDP-galactose Carbohydrate metabolism 95.97 48.50 397.60 27.31 0.24 0.0066**
CMP-N-Acetylneuraminate Nucleotide sugars 12.03 6.19 58.75 6.56 0.20 0.0308*
NAD+ Electron carrier 93.47 65.68 369.37 49.97 0.25 0.0373*
N8-Acetylspermidine Histone acetylation 12.94 10.51 429.06 9.76 0.03 0.0006**
Pelargonic acid Fatty Acids 8.54 8.04 37.42 5.92 0.23 0.0489*
Decanoic acid Fatty Acids 4.10 2.90 19.12 0.43 0.21 0.0150*
Welch’s t-test was used to evaluate the ratios of osteosarcomas (OS) vs. normal fibroblasts (Fb). In more details, all the data derived form OS cells 
(by including all the cell lines together) under acidosis were compared to all the data derived from Fb cells (by including all the different lots of cells 
together). *p < 0.05; **p < 0.01.
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Statistical analysis
For the CE-TOFMS, the data analysis was per-
formed by Welch’s t-test, according to the man-
ufacture suggestions. For all the other assays, 
the statistical analysis was performed with the 
StatViewTM 5.0.1 software (SAS Institute, Cary, 
NC). To evaluate the differences between the 
OS group of data and Fb group of data in cells 
cultured under acidosis, we used the Welch’s 
t-test. To evaluate reduced/oxidized ratio of 
nicotinamide adenine dinucleotide (NADH/
NAD+) statistical differences among neutral OS, 
acidic OS, neutral Fb, and acidic Fb, one-way 
factorial ANOVA and multiple comparison tests 
accompanied by Fisher’s significance were 
applied. Due to the low number of observa-
tions, the other experimental data were consid-
ered as not normally distributed and non-para-
metric tests were used. In these cases, the 
Mann-Whitney U test was used for the differ-
ence between groups. Data were always ex- 
pressed by mean ± standard error (SE), or stan-
dard deviation (SD), which was used only for the 
CE-TOFMS analysis.
Results 
Osteosarcoma metabolic adaptation to acido-
sis
To study the metabolic profile of normal and 
cancer cells, we used CE-TOFMS by which we 
quantified the concentrations of metabolites in 
cell lysates and in the supernatant of both OS 
cells and Fb cultures. Overall, in the analysis, 
243 metabolites were detected, among which 
the concentration of 96 were quantified also 
by using an internal controls as reference. To 
focus on a subgroup of metabolites that are 
specifically associated with tumour-specific 
adaptations to acidosis, we selected a list of 
metabolites that significantly differed in malig-
nant cells (OS) in respect to normal cells under 
acidic conditions. We found that 14 metabo-
lites were significantly decreased in cancer 
cells, whereas none was increased (Table 1). 
The identified decreased metabolites in OS 
were associated with glycolysis, amino acid 
catabolism and urea cycle, e.g. dihydroxyace-
tone phosphate (DHAP), glutamate (Glu), and 
argininosuccinic acid, respectively. Additionally, 
we found in OS cells a decrease in UDP related 
to the metabolic pathway of pyrimidine bases, 
a decrease in oxidized NAD+ related to redox 
status and a decrease in N8-acetylspermidine 
related to histone acetylation. Finally, pelargon-
ic and decanoic acids, which are specifically 
related to fatty acid metabolism, were also sig-
nificantly decreased. For a more comprehen-
sive overview of the metabolic trends under 
acidosis, we also showed the Heat map, includ-
ing additional metabolites that are related to 
the metabolic pathways previously described 
(Supplementary Table S1). All the profilings per-
formed in the present study have been summa-
rized in Figure 1.
Under acidosis osteosarcoma metabolism 
shifts from glycolysis to OXPHOS-TCA 
Among the specific metabolic pathways identi-
fied by the statistical analysis of CE-TOFMS 
data, we focused on glycolysis, TCA and urea 
cycles (Figure 2). Especially in OS cells under 
acidosis, intracellular intermediates of glycoly-
sis/gluconeogenesis were increased, but only 
those upstream of fructose-6-phosphate (F6P) 
and downstream of glucose-1-phosphate (G1P), 
whereas intermediate metabolites that derive 
Figure 2. CE-TOFMS analysis of intracellular metabolites related to the main energetic metabolic pathways after 24 
h of exposure to acidosis: Bar graphs show the relative intracellular amount of metabolites. The bars correspond to 
the mean values of the three OS cell lines included in this study, under neutral (blue) and acidic (red) conditions, 
and to the mean of the two normal Fb cultures under neutral (green) and acidic conditions (orange), mean ± SD. 
Metabolic pathway maps were first written by VANTED software at HMT, and the copyright has been provided to the 
authors. A. Glycolysis/glycogenesis, pentose-phosphate, amino sugar and nucleotide sugar metabolic pathways; B. 
TCA and urea cycles, Glu/Gln metabolic pathway.
Table 2. NADH/NAD+ ratio of both OS and Fb 
cells in neutral vs. acidic conditions, by CE-
TOFMS analysis
NADH/NAD+ (x10-2)
OS Fb
Mean SD Mean SD
Neutral pH 11.35* 4.38 4.51 2.39
Acidic pH 3.36 3.74 1.00 0.33
One-way factorial ANOVA and multiple comparison tests 
accompanied by Fisher’s significance indicated a sig-
nificant difference of NADH/NAD+ ratio in osteosarcoma 
(OS) cells cultured under neutral conditions than in the 
others; acidic OS, neutral fibroblasts (Fb) and acidic Fb. 
(*p < 0.05).
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from fructose-1,6-biphosphate (F1,6BP) (e.g., 
glyceraldehyde 3-phosphate and DHAP) were 
all decreased (Figure 2A). In turn, pentose 
phosphate pathway (PPP) intermediated ribu-
lose-5-phosphate (Ru5P) and sedoheptulose-
7-phosphate (S7P) were unmodified, indicating 
that acidosis induces a metabolic adaptation 
from glycolysis to PPP metabolism. Impaired 
glycolysis in OS cells under acidosis was asso-
ciated with reduced lactate release in cell cul-
ture supernatants (Supplementary Figure S1). 
Although glycolysis was strongly impaired, the 
content of intracellular ATP in OS cells was only 
mildly reduced in Saos-2 and MG-63 cells (up 
to 20% of inhibition), and almost unchanged in 
HOS cells (Supplementary Figure S2), suggest-
ing that metabolic pathways alternative to gly-
colysis are active under acidosis. Under both 
acidic and neutral pH, TCA cycle appeared to be 
used in OS cells as well as in Fb. We observed 
an increased expression of all the complexes of 
OXPHOS, which was significant for complexes I 
and III (Supplementary Figure S3). In addition, 
the transcripts of enzymes related to glycolysis 
and TCA cycles did not change significantly 
under both acidic and neutral pH in both OS 
and Fb (Supplementary Table S2), and almost 
all the intermediates of the TCA cycle in metab-
olomics analysis showed similar levels of con-
centrations, with the exception of succinate in 
acidic OS cells that showed a trend of increase 
(Figure 2B). Finally, NADH/NAD+ ratio was rela-
tively high under neutral pH in OS cells, and 
was drastically reduced under acidosis, sug-
gesting that OS metabolisms shifted from gly-
colysis to oxidative phosphorylation (OXPHOS) 
and TCA cycle (Table 2). 
To ensure that we included in the analysis all 
the significant metabolic pathways associated 
with the metabolic reprogramming of tumour 
cells as a response to extracellular acidosis, we 
performed a statistical analysis of the differ-
ences of the concentration of intracellular me- 
tabolites only in OS cells, between the acidic 
conditions in respect to the neutral conditions 
by the Welch’s t-test (Table 3). Under our expe- 
rimental conditions, malic and fumaric acids 
were significantly decreased (Table 3), and suc-
cinic acid showed a trend for accumulation only 
in malignant OS cells under acidic versus neu-
tral environments (Figure 2B). In our models, a 
decrease in glutamate (Glu) concentration sug-
gested an increase in glutaminolysis to form 
Glu that is immediately used in several meta-
bolic pathways in addition to the TCA cycle 
(Figure 2B), and we found a strong increase in 
all the intermediates of the urea cycle (citrul-
line, L-Arginine [Arg], ornithine, and urea) in OS 
cells under acidosis (Figure 2B).
Low pH promotes the accumulation of amino 
sugar and nucleotide metabolites 
Through the analysis of amino sugar metabo-
lism (Figure 2A), we also observed a specific 
increase in β-D-N-acetylglucosamine (GlcNAc) 
and of its precursor N-acetylglucosamine-6-
phosphate (NAcGlcNP), only in cancer cells. 
The increase in GlcNAc and of NAcGlcNP was 
associated with a reduction of pyrimidine base 
UTP and of purine bases ATP, CTP, and GTP; and 
with an accumulation of guanine, guanosine, 
and adenine (Figure 3A and Supplementary 
Table S1). Adenine and adenosine accumula-
tion might be associated with their increased 
conversion to methyl-thioadenosine (MTA) and 
S-adenosylmethionine (SAM). We further anal-
ysed porphyrin and Gly/Ser/Cys metabolic 
pathways, and we noticed an increase in the 
level of spermine, MTA and SAM in OS cells 
(Figure 3B). In addition to their specific meta-
bolic function, decreases of NAD+, UTP, and 
N8-acetylspermidine (Table 1) can share a com-
mon feature to chromatin regulation. Our profil-
ing data based on the metabolomics approach 
Table 3. Metabolites significantly altered in acidic vs. neutral conditions in OS cells, by CE-TOFMS 
analysis
Compound name Category
Acidic pH Neutral pH
Acidic/
Neutral
P-valueMean 
[pmol/109 cells]
SD Mean 
[pmol/109 cells]
SD
Fumaric acid TCA cycle 4.67 3.30 23.79 3.90 0.20 0.028*
Malic acid TCA cycle, Pyruvate metabolism 50.44 27.82 250.28 52.38 0.20 0.017*
Nicotinamide Cholesterol reducer, Vitamine B 10.86 2.53 3.70 0.95 2.94 0.044*
Glycerophospho choline Glycerol-lipid metabolism, osmolytes 2532.93 637.55 397.00 134.11 6.38 0.037*
Welch’s t-test was used to evaluate the ratios of Acidic vs. Neutral conditions in osteosarcoma (OS) cells. *p < 0.05.
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suggest that metabolic adaptations under aci-
dosis can influence tumour epigenetic altera-
tion as a survival response to a hostile acidic 
microenvironment already after 24 h (Figure 4). 
Therefore, we decided to evaluate the methyla-
tion and acetylation profiles in our model after 
short-term exposure to acidosis. 
Tumour cells that adapt to acidosis have a 
higher epigenetic stability
To evaluate the methylation and acetylation 
profiles in our model after short-term exposure 
to acidosis, OS cells were compared to three 
different primary cultures of mesenchymal 
stromal cells (MSCs), as an additional model of 
normal cells of mesenchymal lineage in addi-
tion to Fb. The profile of methylated genomic 
DNA was evaluated by the COBRA assay. We 
found that an acidic extracellular environment 
histone acetyltransferases (HATs) did not show 
any significant changes (Supplementary Table 
S2). 
Since we realized from our data that the main-
tenance of histone acetylation state is impor-
tant in OS cells cultured under acidic condi-
tions, we finally investigated the effect of HDAC 
inhibitors to be proposed as a targeted therapy 
in acidifying tumour, like OS. We treated HOS 
cells with the class I/IIb HDAC inhibitor (HDACi) 
MC1742 [27, 28] under acidic and neutral con-
ditions. First, the specific activity of the drug 
was confirmed to block HDAC enzymatic activi-
ty by Western blotting analysis at both pHs (pH 
7.4 and 6.5) (Figure 6A). Furthermore, the 
treatment with MC1742 induced a higher dose-
dependent inhibition of cell viability under aci-
dosis than under normal pH conditions (Figure 
6B). The growth inhibition induced by HDAC 
Figure 3. CE-TOFMS analysis of intracellular metabolites related to nucleotide and to Gly/Ser/Cys metabolic path-
way after 24 h of exposure to acidosis: Bar graphs show the relative intracellular amount of metabolites. The bars 
correspond to the mean values of the three OS cell lines under neutral and acidic conditions (blue and red, re-
spectively), and to the mean of the two normal Fb cultures under neutral and acidic conditions (green and orange, 
respectively), mean ± SD. Metabolic pathway maps were first written by VANTED software at HMT, and the copyright 
has been provided to the authors. A. Purine and pyrimidine metabolic pathways; B. Gly/Ser/Cys and porphyrin 
metabolic pathways.
Figure 4. Graphical representation of the metabolic adaptations under aci-
dosis of OS cells, as revealed by the CE-TOFMS analysis: Intracellular me-
tabolites of tumour cells cultured in acidic medium that are reduced (in blue) 
or increased (in red) compared with normal cells cultured in acidic medium 
(0.01 ≤ *p < 0.05 and **p < 0. 01), or with tumour cells cultured under 
neutral conditions (#p < 0.05). The graphics are original and made by the 
authors.
at pH 6.5 for 24 hrs induc- 
ed demethylation of genomic 
DNA in normal cells of mesen-
chymal origin, but not in OS 
cells (Figure 5A). Then, we an- 
alysed the acetylation state of 
OS compared with the state 
of untransformed cells (Fb 
and MSCs) under acidic con-
ditions. In particular, we anal-
ysed the status of histone 
deacetylase 1 (HDAC1) and of 
acetyl-histone H3 (Ac-H3) by 
Western blotting (Figure 5B). 
Interestingly, the acidic extra-
cellular environment did not 
affect the acetylation profile 
of OS cells, whereas it signifi-
cantly reduced HDAC1 and 
enhanced Ac-H3 expression 
(Figure 5B) in almost all pri-
mary cultures of normal cells. 
The reduction of HDAC1 ex- 
pression specifically only in 
normal cells was also con-
firmed by transcriptional scr- 
eening. The other HDAC and 
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under acidosis is possibly due to a block in S 
phase, in addition to G2 phase, as we observed 
by cell cycle analysis (Figure 6C and 6D). 
Discussion 
The role of intratumoral acidosis in cancer pro-
gression is increasingly appreciated especially 
on invasive capacity and the formation of 
metastasis. Also in osteosarcoma, we recently 
demonstrated that acidosis promotes tumour 
aggressiveness [4]. In this study, we wanted to 
further evaluate the feedback effect of this bio-
chemical alteration associated with the tumour 
microenvironment and caused by the altered 
metabolism of glycolytic tumour cells. In par-
ticular, we focused on the rapid metabolic 
response to this stressing condition. Through 
the metabolic profile, we found that in OS cells 
14 metabolites were significantly decreased. 
These were almost all associated with reduced 
glycolysis and amino acid catabolism. In addi-
tion, we found significant reductions of NAD+, 
UTP, and N8-acetylspermidine that are more 
related to epigenetic alteration (Table 1 and 
Figure 4). Notably, tumour and normal cells cul-
tured under short-term acidosis are not dying 
cells, as we directly confirmed through the use 
of viability staining, and the metabolic altera-
tions that we observed in our model define the 
first reaction of tumour cells to adapt to a hos-
tile microenvironment. Our preliminary data 
suggested a reduced glycolytic metabolism of 
OS cells cultured under acidosis, as already 
demonstrated in other cancer [11]. The adapt-
ed metabolism to extracellular acidosis with a 
reduced glycolytic flux affected the prolifera-
tion rate of OS cells leading to an increase in 
the number of cells in G0 phase (Supplementary 
Figure S4). Impaired glycolysis was also associ-
ated with reduced lactate release in OS cell cul-
ture supernatants, thus confirming a repres-
sion of lactate fermentation [29]. Reductions of 
both glycolysis and lactate release in response 
to extracellular acidosis may be an efficient 
feedback system to avoid a further acidification 
of the extracellular space that would ultimately 
lead to an excessive acidification of the cytosol 
and cell death. Adversely, PPP intermediates 
were unmodified, indicating that acidosis induc-
es a metabolic adaptation from glycolysis to 
PPP metabolism, as reported in other cancers 
[11, 12]. Similarly, the maintained and/or in- 
creased expression of the complexes of OX- 
PHOS, indirectly indicated that mitochondrial 
respiration is still used under acidosis [12]. 
Finally, NADH/NAD+ ratio was drastically re- 
duced under acidosis in OS cells (Table 2), sug-
gesting that OS metabolisms shifted from gly-
colysis to OXPHOS-TCA.
Accumulation of succinate is a common featu- 
re of several cancers [29] and NADH-fumarate 
reductase (NADH-FR) system has been involved 
in energy production in some cancers [30-33]. 
Interestingly, under the experimental acidic 
condition, malic and fumaric acids were signifi-
cantly decreased (Table 3), and succinic acid 
showed a trend for accumulation only in malig-
nant OS cells (Figure 2B). In NADH-FR system, 
NADH serves as the electron and proton donor, 
whereas fumarate serves as the ultimate elec-
tron and proton acceptor, with succinate as an 
end product. NADH-FR system still operates 
when the TCA cycle is defective and oxygen is 
limited; therefore, NADH-FR system should be 
considered as a potential source of energy to 
be further explored in cancer cells in hypoxic 
and acidic microenvironments. Several inhibi-
tors of the NADH-FR system [34, 35] or of com-
plex II [36] at the core of this type of alternative 
respiration have been studied as new antican-
cer agents and should also be considered for 
the treatment of hypoxic or acidic cancers like 
OS. Alternatively, in the case of reduced glu-
cose fermentation, amino acid consumption 
(e.g., glutaminolysis), another valuable source 
of energy, is notoriously associated with meta-
bolic acidosis [37, 38] and can be a main source 
of energy production in cancer [39-41], also in 
an acidic microenvironment [12]. In our mod-
els, a decrease in glutamate (Glu) concentra-
tion suggested an increase in glutaminolysis, 
Figure 5. Methylated DNA and histone H3 acetylation in transformed and normal cells under acidosis: (A) Methyla-
tion profile of genomic DNA was screened by COBRA for LINE1 in OS cells, Fb, and MSCs under neutral (N) and 
acidic (A) conditions. Representative image (upper panel), and bar graph (lower panel) of the densitometric analysis 
(mean ± SE, *p < 0.05, n = 3). DNA from NEC8, a testicular embryonal carcinoma, was used as an unmethylated 
control for LINE1. (B) HDAC1 and acetylated histone H3 (Ac-H3) were evaluated by immunoblots in OS cells, Fb, and 
MSCs under both neutral (N) and acidic (A) conditions using specific antibodies. The graphs (lower panel) show the 
densitometric analyses using α-tubulin as control (mean ± SE, *p < 0.05, n = 4). 
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Figure 6. Effect of class I/IIb HDACi on HOS oste-
osarcoma cells under acidosis: A. Western blot-
ting analysis of the acetylation state of histone 
H3 after the treatment with the HDACi MC1742 
at different pHs (upper panel, representative im-
age; lower panel, graph relative to the quantifi-
cation of the bands by software analysis; *p < 
0.05, n = 3); B. Analysis of cell viability by acid 
phosphate indirect assay after the treatment 
with HDACi (mean ± SE, #p vs pH 7.4 at the re-
spective concentration, *p vs. ctr. at the respec-
tive pH; # or *p < 0.05, n = 4); C. Analysis of the 
HDACi effect on the number of cells, counted 
after 72 h of treatment with different concentra-
tions of HDACi. Percentages of inhibitions were 
calculated compared with untreated cells at the 
respective pH (mean ± SE, *p < 0.05, n = 3); 
D. Cell cycle analysis of HOS cells treated with 
HDACi 1 μM at different pHs. Ratio of percent-
ages of treated/untreated cells at the respec-
tive pH, mean ± SE (*p < 0.05).
and a strong increase in all the intermediates of 
the urea cycle was found in OS cells under aci-
dosis. Under physiological conditions, a Glu/
Gln cycle has been associated with increased 
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urea cycle rate in human hepatocytes that 
detoxify ammonia produced from high amino 
acid consumption [42-44]. Therefore, the use 
of Glu analogues such as L-glutamic acid 
γ-monohydroxamate (GAH) in melanomas [45] 
could be explored in the future as an anticancer 
strategy in OS. Under acidosis, the formation of 
ammonia to fuel the urea cycle is also an effi-
cient system to reduce the excess of intracel-
lular protons.
We also observed a specific increase in Glc- 
NAc and NAcGlcNP in cancer cells. GlcNac has 
been associated with O-GlcNacylation, which 
is important for transcriptional control [46]. 
Notably, we recently demonstrated an associa-
tion between the accumulation of amino sugars 
and glucose deprivation in cancer cells [47, 48]. 
The increase in GlcNAc and of NAcGlcNP was 
associated with a reduction of pyrimidine base 
UTP and of purine bases ATP, CTP, and GTP; and 
with an accumulation of guanine, guanosine, 
and adenine. Accumulation of guanine and gua-
nosine might be a consequence of increased 
nucleotide synthesis from Glu, coupled with 
guanine deaminase deficiency in acidic OS, a 
feature that is often observed in malignancies 
[49, 50]. Identifying the type of nucleotide nec-
essary for cancer survival under stress condi-
tions such as acidosis could have an impact in 
cancer therapy since several specific nucleo-
tide analogues are already available and can be 
used in combination with conventional chemo-
therapy [51, 52]. Adenine and adenosine ac- 
cumulation might be associated with their in- 
creased conversion to MTA and SAM; and 
increases of spermine, MTA and SAM were 
noticed in OS cells, indeed. MTA and SAM are 
methyl donors for various substrates, such as 
nucleic acids, proteins, and lipids [53, 54]. In 
addition to their specific metabolic function, 
decreases of NAD+, UTP, and N8-acetylspermi- 
dine can share a common feature to chromatin 
regulation [55, 56]. On the basis of the metabo-
lomics data, we can conclude that the availabil-
ity of certain metabolic substrates is specifi-
cally changed during acidosis in OS cells, thus 
giving a selective advantage to tumour cells. 
Several metabolites have also been associated 
with epigenetic modifications, and metabolic 
adaptations to a stress condition have been 
linked to epigenetic regulation [57]. The ability 
to reprogram metabolic activities under stress 
conditions is responsible for tumour plasticity. 
Under acidosis, the metabolic reprogramming 
of cancer cells is associated with the prompt 
ability to modulate the expression of different 
ion/proton transporters [58, 59] or to increase 
the lysosomal compartment [60]. On the other 
side, it has been reported that acidosis can 
strongly affect the response to hypoxia through 
impairment of HIF-1, inflammation and the 
unfolded protein response [61], thus regulating 
genomic transcriptional outputs. Indeed, our 
profiling data based on the metabolomics 
approach could suggest that metabolic adapta-
tions under acidosis influence tumour epigene-
tic alteration as a survival response to a hostile 
acidic microenvironment already after 24 h 
(Figure 4). So far, the relationship between pH 
and epigenetic modifications has been barely 
studied in cancer. Few reports indicate that his-
tone modification is associated with intracellu-
lar pH regulation [16, 62]. Furthermore, Corbet 
et al. [12] demonstrated that the enzymatic 
activity of NAD-dependent deacetylase sir-
tuin-1 (SIRT1) is differently modulated in cells 
maintained under chronic acidosis. Similarly, 
we investigated the methylation and acetyla-
tion profiles in our model after short exposure 
to acidosis to evaluate the rapid adaptation of 
OS cells to this stressing condition. Interestingly, 
COBRA assay and acetyl-H3 immunoblotting 
indicated an epigenetic stability in OS cells 
than in normal cells. The maintenance of the 
epigenetic profile under stressing conditions is 
a key mechanism for cancer cells to survive 
and to promote genome integrity [63] and clon-
ing efficiency [64]. Furthermore, when we treat-
ed OS cells under acidic and neutral conditions 
with an HDACi MC1742 [27, 28], OS cells were 
more sensitive to the agent under acidosis than 
under neutral pH. At low pH, the growth inhibi-
tion induced by MC1742 was due to a block in 
G2 phase, as reported previously for this class 
of inhibitors [65], with an additional increase 
number of cells blocked also in the S phase. 
Our results thus suggest that the use of HDAC 
inhibitors or other epigenetic modulators can 
affect cancer cells also under an acidic micro-
environment, a condition associated with che-
moresistance in cancers, and should be con-
sidered as a possibly therapeutic strategy in 
the near future, especially for acidifying tumors 
like OS [66, 67]. 
In conclusion, this study demonstrated an 
extensive reprogramming and adaptations of 
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the metabolism of normal and malignant cells 
of mesenchymal origin after an acidic microen-
vironment in the short-term. In particular, we 
found: 1) a reduced glycolytic rate in both nor-
mal and cancer cells; 2) a shift from a Warburg 
glycolytic metabolism to OXPHOS and TCA 
cycles possibly associated with a higher con-
sumption rate of amino acid coupled to an 
increase of urea cycle, especially in cancer 
cells; 3) the metabolic pattern observed in can-
cer cells cultured under acidosis could poten-
tially support the maintenance of the epigene-
tic marks, and finally ensure DNA replication. 
These data offer novel opportunities for the 
identification of effective drugs that can selec-
tively target malignant tumour cells in acidic 
microenvironments. 
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